BMY did the opposite and has given PD-L1 up, probably due to the Medarex story. That could become a regrettable decision in the future.
PS Targeting and IO Combos
I believe you will be correct in regards to Microsoft because Adaptive Biotechnologies to Roche with help from AI and biomarkers required PS Targeting data to build the AI data
I look forward to hearing about Oncologie nondisclosed partners
Royalties and Milestones where the CDMO is all based upon PS Targeting and more hidden behind the John Springs Stafford show